Compare Stocks

Date Range: 

 Fulgent GeneticsBurning Rock BiotechVeracyteGenetronCastle Biosciences
SymbolNASDAQ:FLGTNASDAQ:BNRNASDAQ:VCYTNASDAQ:GTHNASDAQ:CSTL
Price Information
Current Price$70.02$26.14$39.89$18.11$54.56
52 Week RangeHoldBuyBuyBuyBuy
MarketRank™
Overall Score1.41.11.40.41.9
Analysis Score1.12.53.31.53.5
Community Score2.42.53.10.62.9
Dividend Score0.00.00.00.00.0
Ownership Score0.80.00.00.02.5
Earnings & Valuation Score2.50.60.60.00.6
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price Target$74.40$32.30$58.43$19.50$85.00
% Upside from Price Target6.26% upside23.57% upside46.47% upside7.68% upside55.79% upside
Trade Information
Market Cap$2.03 billion$2.73 billion$2.68 billion$1.61 billion$1.37 billion
Beta1.92N/A0.77N/A0.46
Average Volume1,840,918343,180945,257399,740296,100
Sales & Book Value
Annual Revenue$32.53 millionN/A$120.37 million$45.68 million$51.87 million
Price / Sales62.40N/A22.2835.2326.35
Cashflow$0.14 per shareN/AN/AN/A$0.10 per share
Price / Cash498.37N/AN/AN/A539.36
Book Value$4.42 per shareN/A$4.90 per shareN/A$4.98 per share
Price / Book15.84N/A8.1410.96
Profitability
Net Income$-410,000.00N/A$-12,600,000.00$-95,470,000.00$5.28 million
EPS$0.02N/A($0.27)N/A($0.81)
Trailing P/E Ratio34.660.00N/A0.00N/A
Forward P/E Ratio12.97N/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins35.31%N/A-30.46%N/A-5.30%
Return on Equity (ROE)43.81%N/A-12.27%N/A-2.69%
Return on Assets (ROA)36.82%N/A-10.95%N/A-2.05%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.07%
Current Ratio3.39%9.84%26.60%5.74%6.65%
Quick Ratio3.39%9.59%26.28%5.68%6.59%
Ownership Information
Institutional Ownership Percentage33.39%15.79%N/A19.56%66.42%
Insider Ownership Percentage45.00%N/A8.30%N/A39.70%
Miscellaneous
Employees480938320799199
Shares Outstanding28.99 million104.55 million67.24 million88.87 million25.06 million
Next Earnings Date8/3/2021 (Estimated)5/25/2021 (Confirmed)7/29/2021 (Estimated)5/24/2021 (Confirmed)8/9/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
Castle Biosciences (NASDAQ:CSTL) Posts Quarterly  Earnings Results, Beats Expectations By $0.05 EPSCastle Biosciences (NASDAQ:CSTL) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
americanbankingnews.com - May 11 at 3:38 PM
BTIG Stick to Their Buy Rating for Castle BiosciencesBTIG Stick to Their Buy Rating for Castle Biosciences
investing.com - May 11 at 1:42 PM
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Buy" by AnalystsCastle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Buy" by Analysts
americanbankingnews.com - May 11 at 10:19 AM
Tiffany Olson, Seasoned Diagnostics Executive, Joins Castle Biosciences’ Board of DirectorsTiffany Olson, Seasoned Diagnostics Executive, Joins Castle Biosciences’ Board of Directors
finance.yahoo.com - May 11 at 8:42 AM
Castle Biosciences Announces Pipeline Initiative to Develop Genomic Test Targeting Systemic Therapy Response in Patients with Psoriasis, Atopic Dermatitis and Related ConditionsCastle Biosciences Announces Pipeline Initiative to Develop Genomic Test Targeting Systemic Therapy Response in Patients with Psoriasis, Atopic Dermatitis and Related Conditions
businesswire.com - May 11 at 1:52 AM
Castle Biosciences Announces Pipeline Initiative to Develop Genomic Test Targeting Systemic Therapy Response in Patients with Psoriasis, Atopic DermatCastle Biosciences Announces Pipeline Initiative to Develop Genomic Test Targeting Systemic Therapy Response in Patients with Psoriasis, Atopic Dermat
us.acrofan.com - May 10 at 8:51 PM
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue EstimatesCastle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 10 at 8:51 PM
Castle Biosciences (NASDAQ:CSTL) Issues FY 2021 Earnings GuidanceCastle Biosciences (NASDAQ:CSTL) Issues FY 2021 Earnings Guidance
americanbankingnews.com - May 10 at 4:44 PM
Castle Biosciences (NASDAQ:CSTL) Shares Gap Down to $60.32Castle Biosciences (NASDAQ:CSTL) Shares Gap Down to $60.32
americanbankingnews.com - May 10 at 3:26 PM
Update: Castle Biosciences (NASDAQ:CSTL) Stock Gained 79% In The Last YearUpdate: Castle Biosciences (NASDAQ:CSTL) Stock Gained 79% In The Last Year
finance.yahoo.com - May 7 at 12:52 PM
Notable Two Hundred Day Moving Average Cross - CSTLNotable Two Hundred Day Moving Average Cross - CSTL
nasdaq.com - May 6 at 4:39 PM
Castle Biosciences (NASDAQ:CSTL) Earns Buy Rating from Analysts at Lake Street CapitalCastle Biosciences (NASDAQ:CSTL) Earns Buy Rating from Analysts at Lake Street Capital
americanbankingnews.com - May 6 at 4:04 PM
Castle Biosciences (NASDAQ:CSTL) Coverage Initiated by Analysts at Lake Street CapitalCastle Biosciences (NASDAQ:CSTL) Coverage Initiated by Analysts at Lake Street Capital
marketbeat.com - May 6 at 8:50 AM
New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM TestNew Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test
finance.yahoo.com - May 5 at 8:39 AM
Castle Biosciences (NASDAQ:CSTL) Shares Gap Down to $66.71Castle Biosciences (NASDAQ:CSTL) Shares Gap Down to $66.71
americanbankingnews.com - May 4 at 11:06 AM
Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.
finance.yahoo.com - May 4 at 9:44 AM
Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - May 3 at 5:37 PM
Castle Biosciences (CSTL) to Release Quarterly Earnings on MondayCastle Biosciences (CSTL) to Release Quarterly Earnings on Monday
americanbankingnews.com - May 3 at 8:18 AM
Zacks: Analysts Anticipate Castle Biosciences, Inc. (NASDAQ:CSTL) Will Post Quarterly Sales of $17.14 MillionZacks: Analysts Anticipate Castle Biosciences, Inc. (NASDAQ:CSTL) Will Post Quarterly Sales of $17.14 Million
americanbankingnews.com - May 2 at 1:02 AM
Castle Biosciences Supports American Academy of Dermatologys "Skin Cancer, Take a Hike!" Steps Challenge for Skin Cancer Awareness MonthCastle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike!" Steps Challenge for Skin Cancer Awareness Month
wallstreet-online.de - May 1 at 9:53 AM
-$0.22 Earnings Per Share Expected for Castle Biosciences, Inc. (NASDAQ:CSTL) This Quarter-$0.22 Earnings Per Share Expected for Castle Biosciences, Inc. (NASDAQ:CSTL) This Quarter
americanbankingnews.com - April 30 at 8:16 PM
Lake Street Capital Initiates Coverage on Castle Biosciences (NASDAQ:CSTL)Lake Street Capital Initiates Coverage on Castle Biosciences (NASDAQ:CSTL)
americanbankingnews.com - April 30 at 11:44 AM
Castle Biosciences (NASDAQ:CSTL) Now Covered by Analysts at Lake Street CapitalCastle Biosciences (NASDAQ:CSTL) Now Covered by Analysts at Lake Street Capital
marketbeat.com - April 30 at 9:57 AM
Castle Biosciences Supports American Academy of Dermatologys "Skin Cancer, Take a Hike!™" Steps Challenge for Skin Cancer Awareness MonthCastle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike!™" Steps Challenge for Skin Cancer Awareness Month
finance.yahoo.com - April 30 at 8:35 AM
Castle Biosciences (NASDAQ:CSTL) Stock Price Down 5.3%Castle Biosciences (NASDAQ:CSTL) Stock Price Down 5.3%
americanbankingnews.com - April 28 at 1:59 PM
Critical Contrast: Castle Biosciences (NASDAQ:CSTL) vs. Exagen (NASDAQ:XGN)Critical Contrast: Castle Biosciences (NASDAQ:CSTL) vs. Exagen (NASDAQ:XGN)
americanbankingnews.com - April 27 at 8:16 PM
Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® LaboratoryCastle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory
finance.yahoo.com - April 27 at 7:47 AM
DateCompanyBrokerageAction
3/11/2021Fulgent GeneticsPiper SandlerBoost Price Target
2/1/2021Fulgent GeneticsOppenheimerBoost Price Target
1/8/2021Fulgent GeneticsCredit Suisse GroupDowngrade
11/24/2020Fulgent GeneticsBTIG ResearchDowngrade
9/25/2020Fulgent GeneticsCSFBBoost Price Target
11/5/2019Fulgent GeneticsPiper Jaffray CompaniesUpgrade
7/13/2020Burning Rock BiotechBank of AmericaInitiated Coverage
7/7/2020Burning Rock BiotechMorgan StanleyInitiated Coverage
7/7/2020Burning Rock BiotechCowenInitiated Coverage
5/11/2021VeracyteSVB LeerinkLower Price Target
5/11/2021VeracyteNeedham & Company LLCLower Price Target
1/27/2021VeracyteTruistInitiated Coverage
12/17/2020VeracyteLake Street CapitalBoost Price Target
11/9/2020VeracyteKeyCorpInitiated Coverage
11/2/2020VeracyteWilliam BlairReiterated Rating
9/30/2020GenetronCanaccord GenuityReiterated Rating
3/9/2021Castle BiosciencesRobert W. BairdLower Price Target
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.